Whan In Pharm Co.,Ltd.

KSE 016580.KS

Whan In Pharm Co.,Ltd. EBITDA Margin for the year ending December 31, 2023: 18.00%

Whan In Pharm Co.,Ltd. EBITDA Margin is 18.00% for the year ending December 31, 2023, a 3.26% change year over year. EBITDA Ratio is the proportion of Earnings Before Interest, Taxes, Depreciation, and Amortization to total revenue, assessing a company's operational profitability before non-operating expenses and non-cash charges.

Whan In Pharm Co.,Ltd. EBITDA Margin for the year ending December 31, 2022 was 17.43%, a -18.52% change year over year.
Whan In Pharm Co.,Ltd. EBITDA Margin for the year ending December 31, 2021 was 21.39%, a 13.05% change year over year.
Whan In Pharm Co.,Ltd. EBITDA Margin for the year ending December 31, 2020 was 18.92%, a -6.30% change year over year.
Whan In Pharm Co.,Ltd. EBITDA Margin for the year ending December 31, 2019 was 20.19%, a -2.35% change year over year.

Key data

Date	EBITDA Margin	EBIT Margin	Depreciation and Amortization	EBIT

KSE: 016580.KS

Whan In Pharm Co.,Ltd.

CEO	Mr. Wonbum Lee
IPO Date	Jan. 4, 2000
Location	South Korea
Headquarters	Whanin Building, 11
Employees	582
Sector	Health Care
Industries Pharmaceuticals Drugstores & Retail Pharmacies

Description

Whan In Pharm Co.,Ltd., a pharmaceutical company, develops, manufactures, markets, and sells therapeutic products in South Korea. It offers anti-depressants, anti-psychotics, nootropics and anti-dementia, anti-epileptics, cardiovascular, gastrointestinal, antibiotics, antiviral agents, antihistamines, anti-inflammatory and analgesics, metabolic disorders, respiratory, central nervous system, other drug products. The company was founded in 1978 and is headquartered in Seoul, South Korea.

Key trends

Past 5 years